Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Response rate ‐ platinum‐resistant · women with recurrent epithelial ovarian cancer

It is very uncertain whether 175 mg/m2 paclitaxel changes response rate ‐ platinum‐resistant compared with 250 mg/m2 paclitaxel (very low certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
RR 1.34 [0.7, 2.57]
1 study · 52 participants
Very low

Response rate ‐ platinum‐resistant · women with recurrent epithelial ovarian cancer

It is very uncertain whether weekly paclitaxel changes response rate ‐ platinum‐resistant compared with three‐weekly paclitaxel (very low certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
RR 1.01 [0.55, 2.12]
2 studies · 163 participants
Very low